• Products
  • About Us
  • Blog
  • Omixon Academy
  • Resources
  • Contact us
  • Search
  • AzureSeq
  • Request HLA Assay
  • Request HLA Software
  • MyHolotype
You can find all our previous LearnMe Videos here. If you do not find what you are looking for please contact support@omixon.com

HLA Twin Videos

  1. Home ›
    2. Omixon Academy ›
  2. HLA Twin Videos
  • Company Videos
  • HLA Twin Videos
  • Lab TrainMe Videos
  • Posters
  • Workshops
  • Symposium
  • Webinars

Welcome to HLA TWIN Learn Me video series!

Explore more about our NGS Data Analysis Software

loading videos
Loading Videos...

2023 Events calendar

Omixon Blog

Doug Bost became a member of the Scientific Advisory Board for Digital PCR at QIAGEN

10/05/2022
Omixon is entering the field of post-transplant monitoring. To ensure  its position in the market our company has entered...

more

SEE MORE »

Events

BSHI 2022

22/07/2022
  BSHI 2022 | British Society for Histocompatibility and Immunogenetics Conference | 13-14 Sept, 2022, London, UK    The...

more

SEE MORE »

FOLLOW US

TESTIMONIALS

Testimonials

  • “Once again, I congratulate the new version 4.2 of the Twin which is much faster and optimized in processing time and alignment." Romulo Vianna, PhD Rio de Janeiro, State University |UERJ
  • "It's disappointing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
  • “We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
  • "The Holotype HLA method is optimally designed for the service  laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company who work with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
  • “Omixon has developed an excellent direct genotyping method from next generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
  • “NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy to use analytical methods and software tools that aid the generation of accurate results are critical for the success of this ground breaking new technology.”Dr Lajos Pusztai,Professor at the University of Texas MD
    Anderson Cancer Center
  • “Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek
  • "Omixon's Holotype HLA provided greater accuracy with fewer ambiguities, particularly for problematic specimens, than our Sanger SBT procedures."Dr. Pamela Kimball, VCU Health System Authority
  • "The NGS kit for HLA genotyping, unlike others available in the market, provides complete control of the reactions from the beginning to the end of the technical process, thus providing a higher cost-benefit ratio for the Laboratory. HLA TWIN is the best and most complete HLA genotyping program on the market and has helped us solve many problems in our laboratory routine."Dr. Rafael Cita, Fundação Pio XII Barretos
  • "Due to the higher throughput and resolution compared to Sanger sequencing, NGS technology improved significantly HLA typing. Omixon`s Holotype HLA workflow and HLA Twin software could be easily implemented in H&I laboratories. Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT, but also in organ transplantation."Dr. Milena Ivanova, Bulgarian Bone Marrow Registry

 

Omixon Academy

Improve your knowledge!

Our Training Series provide ABHI accredited webinars, workshops, onsite trainings and online demo.

Read more

 

 

Contact Us

Just ask! Get answers!

Your questions and comments are important to us. We’ve got you covered.

Read more

 

 

Omixon Newsletter

Subscribe now!

By clicking 'Ok' I accept the
Privacy Policy

 

Sitemap

Products

  • Holotype HLA™
  • HLA Twin™
  • Monotype HLA™
  • Monotype ABO™
  • HLA Explore™
  • Training and Field Support
  • OmniType™
  • AzureSeq CE

 

Company

  • About
  • Team
  • Board of Directors
  • Scientific Advisory Board
  • CSR Activities
  • Careers / Internships
  • MyHolotype
  • Cooperations and Sponsorships
  • Events

 

Omixon Academy

  • HLA Twin Videos
  • Lab Train Me Videos
  • Posters
  • Workshops
  • Symposiums
  • Webinars
  • Accreditation

 

Contact us

  • Distributors and Agents

Our Mailing Address:

Omixon Biocomputing Ltd.
H-1117 Budapest,
Kaposvár u. 14-18.,
Hungary, EU

US Branch Office:

Omixon Inc.
Suite 265-F
100 Cummings Center
Beverly, MA 01915
USA

sales@omixon.com | www.omixon.com

support@omixon.com

 

2012-2022, Omixon Inc. All Rights Reserved.

We use cookies to improve your experience.

Read more

Omixon | NGS for HLA
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.